StocksInsight

PEN Stock vs the S&P 500: Returns, Risk and Crash History

Penumbra, Inc., healthcare (market value $12.6 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Published Updated 4 min readHow we research

Key takeaways

  • PEN returned +15.3% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it lagged the index.
  • Its 5-year Sharpe ratio was 0.17 against 0.58 for the S&P 500.
  • Its deepest crisis drawdown was −59.1% in the 2022 inflation bear market (S&P 500: −25.4%).
  • Five‑year volatility was 40.7% and beta 0.71.
  • 16 analysts rated it in the past year; 17% of their latest calls were Buy.
  • PEN beat earnings estimates in 9 of its last 12 reports; the stock moved 6.2% on average, up or down, around each report.

What do the best‑ranked analysts on PEN say now? See it in Exent Gems →

Did PEN beat the S&P 500?

Over the 5 years to Oct 30, 2026, Penumbra, Inc. (PEN) returned +15.3% including dividends, versus +75.9% for the S&P 500 (SPY). It lagged the index by 60.6 percentage points, or +2.9% a year against +12.0%.

PeriodPENS&P 500PEN per yearS&P 500 per yearResult
1 year+40.3%+12.0%+40.3%+12.0%Beat
3 years+66.9%+87.4%+18.6%+23.3%Lagged
5 years+15.3%+75.9%+2.9%+12.0%Lagged
10 years+383.6%+316.3%+17.1%+15.3%Beat
  • 1 year
    PEN
    +40.3%
    S&P 500
    +12.0%
    PEN per year
    +40.3%
    S&P 500 per year
    +12.0%
    Result
    Beat
  • 3 years
    PEN
    +66.9%
    S&P 500
    +87.4%
    PEN per year
    +18.6%
    S&P 500 per year
    +23.3%
    Result
    Lagged
  • 5 years
    PEN
    +15.3%
    S&P 500
    +75.9%
    PEN per year
    +2.9%
    S&P 500 per year
    +12.0%
    Result
    Lagged
  • 10 years
    PEN
    +383.6%
    S&P 500
    +316.3%
    PEN per year
    +17.1%
    S&P 500 per year
    +15.3%
    Result
    Beat

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.

What Wall Street analysts say about PEN

In the 12 months to 30 days ago, 16 analysts published 115 ratings on PEN. Their latest calls were 17% Buy, 83% Hold and 0% Sell. 1 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $320.00 (range $320.00–$320.00), −0.2% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?

Top‑ranked analyst coveringFirmStarsPrice‑target hit rate
Vijay KumarEvercore ISI4.5★55.6%

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on PEN are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.

PEN returns by year vs the S&P 500

PEN beat the S&P 500 in 5 of the 9 full calendar years shown.

YearPENS&P 500Difference
2026 (to Oct 30, 2026)+2.6%+11.7%−9.1%
2025+30.9%+17.7%+13.2%
2024−5.6%+24.9%−30.5%
2023+13.1%+26.2%−13.1%
2022−22.6%−18.2%−4.4%
2021+64.2%+28.7%+35.5%
2020+6.5%+18.3%−11.8%
2019+34.4%+31.2%+3.2%
2018+29.9%−4.6%+34.5%
2017+47.5%+21.7%+25.8%

PEN risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, PEN had a Sharpe ratio of 0.17 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 39.6% and its beta 0.71: it tended to move about 0.7× as much as the market.

MetricPENS&P 500
Annual return+2.9%+12.0%
Volatility (annualized)39.6%15.5%
Sharpe ratio0.170.58
Sortino ratio0.270.91
Max drawdown (month-end)−56.7%−23.9%
Beta to the S&P 5000.711.00

Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

How PEN behaved in past crashes

PEN’s deepest fall in the crises below was −59.1% in the 2022 inflation bear market, against −25.4% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

CrisisPENS&P 500Loss on $100,000
2018 trade-war selloff−27.5%−20.2%−$27,520
COVID crash (Feb–Mar 2020)−35.8%−34.1%−$35,830
2022 inflation bear market−59.1%−25.4%−$59,120
2025 tariff selloff−15.8%−19.0%−$15,780
WindowPEN max drawdown
Last 1 year−21.4%
Last 3 years−52.4%
Last 5 years−60.1%
Last 10 years−62.6%

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.

What moves with PEN, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, PEN’s correlation with the S&P 500 was 0.28, with the Nasdaq‑100 0.24, with long Treasuries (TLT) 0.34 and with gold (GLD) 0.18.

Adding a 5% PEN position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.4%.

Least correlated large capsCorrelationMost correlated large capsCorrelation
DELL−0.17SYK0.47
XOM−0.13UBER0.46
GD−0.12SBUX0.44
LMT−0.09ICE0.42
ORCL−0.08RCL0.40

Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.

Latest PEN upgrades, downgrades and price‑target changes

No named analyst changed a rating or price target on PEN in the 5 weeks to Oct 20, 2026 (calls are shown 30 days after publication). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.

Do analysts get PEN right?

Of the 310 analyst price targets on PEN set from 2019 until a year ago, 78.7% were reached within 12 months (data to Oct 20, 2026), 10.1 points above the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 63 days. The median target sat 16.0% above the share price on the day it was set.

Where analysts said PEN would be by now: a year ago, 11 analysts had a price target on PEN, and the median of their latest targets was $320.00. On Oct 20, 2026 PEN closed at $324.35, 1.4% above it.

78.7%of targets reached within 12 monthsMedian stock: 68.6%
63 daysmedian time to reach a target
+1.4%price now vs the median target set a year ago
AfterCallsMove on the call3 months vs S&P 500
Upgrades of PEN11+4.9%+9.4%
Upgrades, all stocks11,514+2.5%+3.4%
Downgrades of PEN18+1.6%−0.2%
Downgrades, all stocks10,700−3.0%−1.6%

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on PEN through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?

How PEN moves after earnings

PEN beat the consensus earnings‑per‑share estimate in 9 of its last 12 quarterly reports, through the one on Jul 30, 2026, and the revenue estimate in 8 of 12. From the close before each report to the close after it, the stock moved 6.2% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 9 of the 12 reports. In 2 of the 9 beats the stock still fell.

9/12earnings beats
±6.2%average move per report
9/12reports followed by a rise
ReportEPS vs estimateRevenue vs estimateStock move
Jul 30, 2026$0.88 vs $1.16+0.1%+0.3%
May 6, 2026$0.82 vs $1.04+1.2%+0.2%
Feb 25, 2026$1.18 vs $1.11+6.5%+0.7%
Nov 5, 2025$0.97 vs $0.93+4.0%+12.6%
Jul 29, 2025$0.86 vs $0.81−0.6%+10.4%
Apr 23, 2025$0.83 vs $0.66−1.0%+7.6%
Feb 18, 2025$0.97 vs $0.88+1.2%+13.1%
Oct 30, 2024$0.85 vs $0.69−3.4%+9.2%

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings

Where PEN’s revenue comes from

In fiscal 2025 (the year to Dec 31, 2025), PEN’s largest reported region was the United States, with 77.8% of its $1.4 billion revenue. By region: United States 77.8%; Non-US 22.2%.

By business, the largest segment was Peripheral Vascular, with 59.0% of $847.1 million revenue (+22.1% on the year before).

  • United States77.8%
  • Non-US22.2%
SegmentRevenueShareGrowth
Peripheral Vascular$499.4 million59.0%+22.1%
Neuro$347.7 million41.0%+2.7%

From PEN’s annual filings; segment growth compares fiscal 2022 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?

Members of Congress who traded PEN

As of Oct 20, 2026, 2 members of Congress had disclosed 7 trades in PEN (3 buys and 4 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated Jul 10, 2025.

Trade dateMemberTypeAmount
Jul 10, 2025Lisa McClainSale$1,001–$15,000
Jun 27, 2022Ro KhannaSale$1,001–$15,000
May 23, 2022Ro KhannaSale$1,001–$15,000
May 10, 2022Ro KhannaBuy$1,001–$15,000
May 5, 2022Ro KhannaBuy$1,001–$15,000
Jan 21, 2022Ro KhannaBuy$1,001–$15,000
Jan 11, 2022Ro KhannaSale$1,001–$15,000

Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades

Are PEN insiders buying or selling?

In the 12 months to Oct 20, 2026, PEN insiders made no open‑market purchases and 4 sales worth $11.1 million, according to SEC Form 4 filings. The last open‑market purchase on record was on May 25, 2018.

After the 2 insider purchases of $10,000 or more since 2012, PEN beat the S&P 500 by an average of 14.6 percentage points over the next 12 months; 50% of them were followed by a beat (a small sample). Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

Q1 ’25
Q2 ’25
Q3 ’25
Q4 ’25
Q1 ’26
Q2 ’26
Q3 ’26
Q4 ’26
DateInsiderRoleValue
May 25, 2018O'Rourke BridgetDirector$109,480
May 19, 2016Evans Robert D.EVP, Gen. Counsel & Secretary$39,219

The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?

How much of PEN is sold short?

As of the Sep 30, 2026 settlement date, 5.87% of PEN’s float was sold short: 2.2 million shares, or 4.8 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 4.53%. The median across the 997 US stocks Exent tracks was 4.77%, so PEN is more heavily shorted than most.

  • Apr 30, 20264.96%
  • May 29, 20265.01%
  • Jun 30, 20265.32%
  • Jul 31, 20264.80%
  • Aug 31, 20264.52%
  • Sep 30, 20265.87%

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks

How many institutions own PEN?

At the end of Q2 2026 (Jun 30, 2026), 475 institutions reported holding PEN in 13F filings, down 24 from the quarter before and up from 475 a year earlier. Their reported holdings add up to 87.8% of PEN’s shares. In the quarter 195 institutions added to their positions and 186 cut them.

47513F holders
48new positions
76positions closed
87.8%of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling

Is PEN diluting shareholders?

PEN’s diluted share count rose 9.9% over the five fiscal years to fiscal 2025 and rose 0.1% in fiscal 2025 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $59.2 million in fiscal 2025, 4.2% of revenue. PEN did not buy back shares in fiscal 2025.

+0.1%share count, 1 year
+9.9%share count, 5 years
4.2%stock pay as % of revenue
0.00%buyback yield

Weighted‑average diluted shares from PEN’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained

PEN financial health scores

In Exent’s Oct 20, 2026 snapshot, PEN’s Altman Z‑score was 19.16, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 5 out of 9; 80% of scored stocks reach 5 or more.

19.16Altman Z‑score: safe zone
5/9Piotroski F‑score

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?

Which ETFs hold PEN?

As of Oct 20, 2026, 32 of the 304 ETFs Exent tracks held PEN. Its largest weight is in IJK (iShares S&P Mid-Cap 400 Growth ETF), at 0.63% of the fund.

ETFFundWeight of PEN
IJKiShares S&P Mid-Cap 400 Growth ETF0.63%
IJHiShares Core S&P Mid-Cap ETF0.38%
SPMDState Street SPDR Portfolio S&P 400 Mid Cap ETF0.38%
MDYState Street SPDR S&P MIDCAP 400 ETF Trust0.37%
IWPiShares Russell Mid-Cap Growth ETF0.36%
VBKVanguard Small-Cap Growth Index Fund ETF Shares0.34%
SCHMSchwab U.S. Mid-Cap ETF0.27%
JQUAJPMorgan U.S. Quality Factor ETF0.19%

Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?

The right benchmark for PEN

Exent matches every holding to the index with the most similar risk. For PEN that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.

Other healthcare stocks

TickerName5‑year returnVolatility (5y)
LLYEli Lilly and Company+482.3%32.6%
JNJJohnson & Johnson+92.9%16.8%
ABBVAbbVie Inc.+207.1%23.5%
AMRXAmneal Pharmaceuticals, Inc.+291.8%49.8%
BAXBaxter International Inc.−67.9%36.1%
CHEChemed Corporation+12.9%25.4%
SOLVSolventum Corporation——
BLTEBelite Bio, Inc——

Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Check PEN with Exent Gems

Wall Street’s average PEN price target is in line with the latest share price. See what the best‑ranked analysts on PEN say now in Exent Gems.

  1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
  2. Gems shows who the top‑ranked analysts covering PEN are, their live calls and the median target of only the top‑rated analysts.
  3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

Yes. PEN returned +383.6% (+17.1% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

No. As of Oct 20, 2026, PEN (Penumbra, Inc.) is not one of the 503 stocks in the S&P 500.

PEN fell −35.8% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

PEN fell −59.1% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

Over the 5 years to Oct 30, 2026, PEN’s Sharpe ratio was 0.17 and its Sortino ratio 0.27, versus 0.58 and 0.91 for the S&P 500.

PEN’s 5‑year annualized volatility was 40.7%, higher than the S&P 500’s 17.0%, with a beta of 0.71.

Among large US stocks, the lowest correlations with PEN over the last 60 months were DELL (−0.17), XOM (−0.13), GD (−0.12). Its correlation with long Treasuries (TLT) was 0.34 and with gold (GLD) 0.18.

PEN beat the consensus earnings-per-share estimate in 9 of its last 12 quarterly reports through Jul 30, 2026, and the revenue estimate in 8 of 12. The stock moved 6.2% on average, up or down, from the close before each report to the close after it.

Yes. As of Oct 20, 2026, 2 members of Congress had disclosed 7 trades in PEN (3 buys and 4 sales) in STOCK Act disclosures filed with the House and Senate.

As of the Sep 30, 2026 settlement date, 5.87% of PEN’s float was sold short (2.2 million shares, 4.8 days to cover), according to FINRA short-interest reports. A year earlier it was 4.53%.

Yes. PEN’s diluted share count rose 9.9% over the five fiscal years to fiscal 2025 and rose 0.1% in the latest year. Stock-based compensation was 4.2% of revenue.

What do the best‑ranked analysts say on PEN now?

Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on PEN are, their latest calls and the stocks where several of them agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.